Read the Docket, Beat the Market: How Litigation Data Tells You When a Generic Drug Will Launch
Arbitraging the Patent Cliff: Using Litigation Dockets to Forecast Generic Entry Pharmaceutical patent litigation determines the timing of billions of
Insights
The Price of Access: How Drug Money Flows Into the FDA — and What It Actually Buys
The Question That Makes Regulators Uncomfortable The FDA approves drugs that can kill or cure hundreds of millions of people.
The Price of Access: How Drug Money Flows Into the FDA — and What It Actually Buys Read Post »
Pharmaceutical Competitor Analysis: The Complete Strategic Playbook for IP Teams, R&D Leads, and Institutional Investors
1. What Pharmaceutical Competitor Analysis Actually Is Definition and Scope Pharmaceutical competitor analysis is the systematic collection, validation, and interpretation
Why Orange Book Expiration Dates Don’t Match Real Generic Drug Market Entry Dates (and what to use instead)
The pharmaceutical industry is fundamentally governed by the tension between innovation incentives and market competition, a balance primarily mediated through
Patent vs. Regulatory Exclusivity The Critical Difference in Forecasting a Drug’s Market Longevity
The strategic landscape of the pharmaceutical industry is defined by a paradoxical relationship between regulatory transparency and market reality. At
The LOE Sales Playbook: 100 Revenue Triggers for Pharmaceutical Supply Vendors
Convert patent expiry timelines into predictable revenue workflows. For senior executives at CDMOs · API manufacturers · excipient suppliers ·
The LOE Sales Playbook: 100 Revenue Triggers for Pharmaceutical Supply Vendors Read Post »
“We Missed the LOE Date”: How Pharma Vendors Lose Millions by Tracking Expiry Wrong
The global pharmaceutical industry is currently undergoing a structural realignment driven by a contraction of revenue that is unprecedented in
“We Missed the LOE Date”: How Pharma Vendors Lose Millions by Tracking Expiry Wrong Read Post »
The Patent Cliff Illusion: Why Generics Don’t Always Launch
I. Introduction: Beyond the Patent Cliff—The Hidden Realities of Generic Entry In the high-stakes world of the pharmaceutical industry, the
The Patent Cliff Illusion: Why Generics Don’t Always Launch Read Post »
High-Yield Hedging: Using Patent Landscape Data to Navigate Generic Entry and Revenue Erosion
The Revenue Cliff Is Predictable — And Yet Companies Keep Falling Off It In 2011, Pfizer watched approximately $10.7 billion
